

Table 1.

Drug Interactions Between Direct-Acting Antivirals and Antiretroviral Drugs—Preferred Regimens

Green indicates coadministration is safe; yellow indicates a dose change or additional monitoring is warranted; and pink indicates the combination should be avoided.

	Ledipasvir/ Sofosbuvir (LDV/SOF)	Sofosbuvir/ Velpatasvir (SOF/VEL)	Elbasvir/ Grazoprevir (ELB/GRZ)	Glecaprevir/ Pibrentasvir (GLE/PIB)	Sofosbuvir/ Velpatasvir/ Voxilaprevir (SOF/VEL/VOX)
Ritonavir-boosted atazanavir (ATZ)	▲ LDV ▲ ATZ ^a	▲ VEL ▲ ATZ ^a	▲ ELB ▲ GRZ ▲ ATZ	ND	▲ ATZ
Ritonavir-boosted darunavir (DRV)	▲ LDV ↔ DRV ^a	↔ VEL ↔ DRV ^a	▲ ELB ▲ GRZ ↔ DRV	ND	▲ VOX ↔ DRV
Ritonavir-boosted lopinavir (LPV)	ND ^a	↔ VEL ↔ LPV ^a	▲ ELB ▲ GRZ ↔ LPV	ND	ND
Ritonavir-boosted tipranavir (TPV/r)	ND	ND	ND	ND	ND
Efavirenz (EFV)	▼ LDV ▼ EFV ^a	▼ VEL ▼ EFV	▼ ELB ▼ GRZ ▼ EFV	ND	ND
Rilpivirine (RPV)	↔ LDV ↔ RPV	↔ VEL ↔ RPV	↔ ELB ↔ GRZ ↔ RPV	↔ GLE ↔ PIB ▲ RPV	↔ VEL ↔ VOX ↔ RPV
Etravirine (ETV)	ND	ND	ND	ND	ND
Raltegravir (RAL)	↔ LDV ↔ RAL	↔ VEL ↔ RAL	↔ ELB ↔ GRZ ▲ RAL	↔ GLE ↔ PIB ▲ RAL	ND
Cobicistat-boosted elvitegravir (COB)	▲ LDV ▲ COB ^a	▲ VEL ▲ COB ^a	▲ ELB ▲ GRZ ▲ COB	▲ GLE ▲ PIB ▲ COB	▲ VOX ▲ COB ^a
Dolutegravir (DTG)	↔ LDV ↔ DTG	↔ VEL ↔ DTG	↔ ELB ↔ GRZ ▲ DTG	▼ GLE ▼ PIB ▲ DTG	ND
Maraviroc (MVC)	ND	ND	ND	ND	ND
Tenofovir (TFV) disoproxil fumarate	↔ LDV ▲ TFV ^c	↔ VEL ▲ TFV	↔ ELB ↔ GRZ ▲ TFV	ND	▲ TFV ^b
Tenofovir (TFV) alafenamide	↔ LDV ▲ TFV ^d	↔ VEL ▲ TFV ^d	ND	↔ GLE ↔ PIB ↔ TFV	▲ TFV ^b

ND, No data

^a Caution only with tenofovir disoproxil fumarate

^b Increase in tenofovir depends on which additional concomitant antiretroviral agents are administered.

^c Avoid tenofovir disoproxil fumarate in patients with an eGFR <60 mL/min; tenofovir concentrations may exceed those with established renal safety data in individuals on ritonavir- or cobicistat-containing regimens.

^d Studied as part of fixed-dose combinations with ledipasvir/sofosbuvir or sofosbuvir/velpatasvir plus TAF, emtricitabine, elvitegravir, and cobicistat.

Table 2.

Drug Interactions Between Direct-Acting Antivirals and Antiretroviral Drugs—Alternative Regimens

Green indicates coadministration is safe; yellow indicates a dose change or additional monitoring is warranted; and pink indicates the combination should be avoided.

	Simeprevir/ Sofosbuvir (SMV/SOF)	Daclatasvir/ Sofosbuvir (DCV/SOF)	Paritaprevir/ Ritonavir/ Ombitasvir + Dasabuvir (PrOD)	Paritaprevir/ Ritonavir/ Ombitasvir (PrO)
Ritonavir- boosted atazanavir (ATZ)	ND	▲ DCV ^a	▲ PRV ▲ ATZ	▲ PRV ↔ ATZ
Ritonavir- boosted darunavir (DRV)	▲ SMV ↔ DRV	▲ DCV ↔ DRV	▼▲ PRV ▼ DRV	▲ PRV ↔ DRV
Ritonavir- boosted lopinavir (LPV)	ND	▲ DCV ↔ LPV	▲ PRV ↔ LPV	▲ PRV ↔ LPV
Ritonavir- boosted tipranavir (TPV/r)	ND	ND	ND	ND
Efavirenz (EFV)	▼ SMV ↔ EFV	▼ DCV ^b	NPD ^c	ND
Rilpivirine (RPV)	↔ SMV ↔ RPV	ND	▲ PRV ▲ RPV	ND
Etravirine (ETV)	ND	▼ DCV ^b	ND	ND
Raltegravir (RAL)	↔ SMV ↔ RAL	ND	↔ PrOD ▲ RAL	↔ PrO ▲ RAL
Cobicistat- boosted elvitegravir (COB)	ND	▲ DCV ^a	ND	ND
Dolutegravir (DTG)	↔ SMV ↔ DTG	↔ DCV ▲ DTG	▼ PRV ▲ DTG	ND
Maraviroc (MVC)	ND	ND	ND	ND
Tenofovir (TFV) disoproxil fumarate	↔ SMV ↔ TFV	↔ DCV ↔ TFV	↔ PrOD ↔ TFV	↔ PrO ↔ TFV
Tenofovir (TFV) alafenamide	ND	ND	ND	ND

ND, No data
^a Daclatasvir dose should be reduced to 30 mg.
^b Daclatasvir dose should be increased to 90 mg.